Trial comparisons

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=38

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00069784-sae",
        "title": "Insulin Glargine vs Standard Care: serious adverse events",
        "summary": "303 of 6231 against 232 of 6273; risk difference 1.2 points, 95% interval 0.5 to 1.9; NCT00069784, The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)",
        "record": "/library/comparisons/NCT00069784-sae",
        "nct_id": "NCT00069784",
        "kind": "serious-adverse-events",
        "participants": 12504,
        "risk_difference": {
          "value": 0.011643929348183563,
          "lower": 0.004552118447227021,
          "upper": 0.018781104279081712
        },
        "group_1": "303 of 6,231",
        "group_2": "232 of 6,273",
        "difference": "1.2 points",
        "interval": "0.5 to 1.9",
        "trial_title": "The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)"
      },
      {
        "id": "NCT05168813-49517fe3",
        "title": "Part A (Open-label): Analysis Group 1 (AG1) + Analysis Group 3 (AG3) vs Part A (Open-label): Analysis Group 2-1 (AG2-1) + Analysis Group 4-1 (AG4-1): Part A: Number of Participants With First COVE-based COVID-19 Occurrence From 1 Day After Month 0 Dose to Month 6 Dose in FAS Cohort, Comparing Baseline SARS-CoV-2 Negative vs Positive, Regardless of HIV Statu",
        "summary": "34 of 2867 against 45 of 9613; risk difference 0.7 points, 95% interval 0.3 to 1.2; NCT05168813, Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern",
        "record": "/library/comparisons/NCT05168813-49517fe3",
        "nct_id": "NCT05168813",
        "kind": "outcome",
        "participants": 12480,
        "risk_difference": {
          "value": 0.0071779252248628115,
          "lower": 0.0034663582357945715,
          "upper": 0.011991500697639549
        },
        "group_1": "34 of 2,867",
        "group_2": "45 of 9,613",
        "difference": "0.7 points",
        "interval": "0.3 to 1.2",
        "trial_title": "Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=39",
  "request_id": "xwV3pvjbywGTk_2I"
}